BioSpace News Archive

Can-Fite Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT™ Study in Moderate to Severe Psoriasis.

btt Corp. (btt), a medical technology company focused on the development of innovative devices and treatments for targeted heat shock protein induction, today announced that Oklahoma Rock Holdings, LLC (Oklahoma Rock) has completed an investment of $29.3 million.

Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger’s novel platform technology for blood-based early cancer detection.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development.

Hemodialysis Technology Company Diality Joins Innovative Kidney Care Campaign, Seeks to Improve Choice for Kidney Patients.

Elite Pharmaceuticals, Inc. announced that it received approval from the US Food and Drug Administration for an Abbreviated New Drug Application for a generic version of Sabril® 500 mg powder for solution packet.

Galera Therapeutics, Inc. today announced results from the open-label Phase 1 stage of the GRECO-1 trial of rucosopasem in combination with stereotactic body radiation therapy (SBRT) in patients with centrally located or large non-small cell lung cancer (NSCLC).

Mindset Pharma Inc. today announced that the Company has developed a novel, patent-pending, intranasal platform formulation technology expected to deliver improved central system (CNS) penetration of first and subsequent generations of psychedelic medicines.

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMA Productive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program design.

If approved, extended regimen would provide a longer treatment interval and additional dosing flexibility, alongside approved every 4- and 8-week dosing regimens.